Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 6(66), 2022
DOI: 10.1128/aac.02264-21
Links
Tools
Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis
Journal article published in 2022 by
Louvina E. van der Laan 
,
Anthony J. Garcia-Prats ,
H. Simon Schaaf,
Maxwell Chirehwa ,
Jana L. Winckler,
Jun Mao,
Heather R. Draper,
Lubbe Wiesner ,
Jennifer Norman,
Helen McIlleron ,
Peter R. Donald,
Anneke C. Hesseling,
Paolo Denti ,
Others
,
Anthony J. Garcia-Prats ,
H. Simon Schaaf,
Maxwell Chirehwa ,
Jana L. Winckler,
Jun Mao,
Heather R. Draper,
Lubbe Wiesner ,
Jennifer Norman,
Helen McIlleron ,
Peter R. Donald,
Anneke C. Hesseling,
Paolo Denti ,
Others
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Treatment options for children with Rifampicin-resistant tuberculosis (RR-TB) remain limited, and para-aminosalicylic acid (PAS) is still a relevant component of treatment regimens. Prevention of resistance to companion drugs by PAS is dose related, and at higher concentrations, PAS may exhibit significant bactericidal activity in addition to its bacteriostatic properties.